The Goodes Prize for Excellence in Drug Development honors an innovative researcher who has made a significant and lasting impact in the field.

The Goodes Prize – recognized as the Nobel Prize of Alzheimer’s research – celebrates an exceptional scientist whose groundbreaking work has made a profound and enduring impact on the field of Alzheimer’s research.

At a moment of unprecedented optimism in Alzheimer’s research, it is vital to accelerate progress toward transformative treatments, innovative biomarkers, and strategies that will treat, prevent, and ultimately cure, this disease.

Named in honor of Melvin R. Goodes, a visionary leader in the pharmaceutical industry whose breakthroughs improved millions of lives, the prize recognizes those who embody the same spirit of excellence, ingenuity, and perseverance.

As a global leader in advancing the most promising science, the Alzheimer’s Drug Discovery Foundation is proud to award the Goodes Prize, which includes $150,000 to propel the recipient’s future research and bring us closer to ending Alzheimer’s.

Winners

2015: Frank Longo, MD, PhD

2016: D. Martin Watterson, PhD

2017: Roberta Diaz Brinton, PhD

2018: Michela Gallagher, PhD

2019: Jeffrey Cummings, MD

2020: Jerri M. Rook, PhD

2021: Miia Kivipelto, MD, PhD

2022: Miranda E. Orr, PhD

2023: Rhoda Au, PhD, MBA

2024: Henrik Zetterberg, MD, PhD

2025: Daniel M. Skovronsky, MD, PhD